E
INVO Bioscience, Inc.
INVO
$1.72
-$0.379-18.05%
E
Sell
3/14/2023Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 02/09/2023.
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.07 to 0.18, and the quick ratio declined from 1.58 to 0.21.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.07 to 0.18, and the quick ratio declined from 1.58 to 0.21.
D
Sell
11/7/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 11/7/2022 due to an increase in the total return index, valuation index and volatility index.
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 11/7/2022 due to an increase in the total return index, valuation index and volatility index.
D
Sell
10/21/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 10/21/2022 due to a decline in the valuation index.
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 10/21/2022 due to a decline in the valuation index.
D
Sell
10/6/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and total return index.
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 10/6/2022 due to an increase in the volatility index and total return index.
D
Sell
9/7/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 9/7/2022 due to a decline in the volatility index.
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 9/7/2022 due to a decline in the volatility index.
D
Sell
8/19/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 8/19/2022 due to a noticeable increase in the growth index. Operating cash flow increased 9.88% from -$2.08M to -$1.87M, and EBIT increased 0.71% from -$2.7M to -$2.68M.
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 8/19/2022 due to a noticeable increase in the growth index. Operating cash flow increased 9.88% from -$2.08M to -$1.87M, and EBIT increased 0.71% from -$2.7M to -$2.68M.
D
Sell
5/19/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 5/19/2022 due to a substantial decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0158 to -$0.2302, EBIT declined 636.32% from $503.6 to -$2.7M, and total revenue declined 94.67% from $3.05M to $162.6.
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 5/19/2022 due to a substantial decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0158 to -$0.2302, EBIT declined 636.32% from $503.6 to -$2.7M, and total revenue declined 94.67% from $3.05M to $162.6.
D
Sell
5/16/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 05/16/2022.
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
INVO Bioscience, Inc. (INVO) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 4/18/2022 due to a major increase in the growth index, solvency index and valuation index. Total revenue increased 1,292.51% from $218.9 to $3.05M, EBIT increased 122.15% from -$2.27M to $503.6, and the quick ratio increased from 2.23 to 4.58.
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 4/18/2022 due to a major increase in the growth index, solvency index and valuation index. Total revenue increased 1,292.51% from $218.9 to $3.05M, EBIT increased 122.15% from -$2.27M to $503.6, and the quick ratio increased from 2.23 to 4.58.
D
Sell
3/15/2022Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 3/15/2022 due to a decline in the total return index.
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 3/15/2022 due to a decline in the total return index.
D
Sell
2/18/2022Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 2/18/2022 due to an increase in the total return index.
INVO Bioscience, Inc. (INVO) was upgraded to D from D- on 2/18/2022 due to an increase in the total return index.
D
Sell
11/17/2021Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to D- from E+ on 11/17/2021 due to an increase in the growth index and volatility index. Total revenue increased 4.99% from $208.5 to $218.9.
INVO Bioscience, Inc. (INVO) was upgraded to D- from E+ on 11/17/2021 due to an increase in the growth index and volatility index. Total revenue increased 4.99% from $208.5 to $218.9.
E
Sell
11/8/2021Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the valuation index.
INVO Bioscience, Inc. (INVO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the valuation index.
D
Sell
12/29/2020Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 12/29/2020 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 0.97 to 0.48, earnings per share declined from -$0.272 to -$0.36, and debt to equity increased from -0.28 to -0.2.
INVO Bioscience, Inc. (INVO) was downgraded to D- from D on 12/29/2020 due to a noticeable decline in the growth index, solvency index and total return index. The quick ratio declined from 0.97 to 0.48, earnings per share declined from -$0.272 to -$0.36, and debt to equity increased from -0.28 to -0.2.
D
Sell
5/1/2020Downgrade
INVO Bioscience, Inc. (INVO) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, volatility index and valuation index.
INVO Bioscience, Inc. (INVO) was downgraded to D from C- on 5/1/2020 due to a significant decline in the efficiency index, volatility index and valuation index.
C
Hold
4/24/2020Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to C- from D+ on 4/24/2020 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from -0.09 to -0.1, and total revenue increased 8.23% from $303.6 to $328.6.
INVO Bioscience, Inc. (INVO) was upgraded to C- from D+ on 4/24/2020 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from -0.09 to -0.1, and total revenue increased 8.23% from $303.6 to $328.6.
D
Sell
12/2/2019Downgrade
INVO Bioscience, Inc. (IVOB) was downgraded to D+ from C- on 12/2/2019 due to a large decline in the growth index, volatility index and total return index. EBIT declined 861.09% from -$65.8 to -$632.4, earnings per share declined from -$0.0016 to -$0.0046, and total revenue declined 53.9% from $658.6 to $303.6.
INVO Bioscience, Inc. (IVOB) was downgraded to D+ from C- on 12/2/2019 due to a large decline in the growth index, volatility index and total return index. EBIT declined 861.09% from -$65.8 to -$632.4, earnings per share declined from -$0.0016 to -$0.0046, and total revenue declined 53.9% from $658.6 to $303.6.
C
Hold
10/8/2019Downgrade
INVO Bioscience, Inc. (IVOB) was downgraded to C- from C on 10/8/2019 due to a decline in the volatility index.
INVO Bioscience, Inc. (IVOB) was downgraded to C- from C on 10/8/2019 due to a decline in the volatility index.
C
Hold
8/19/2019Upgraded
INVO Bioscience, Inc. (IVOB) was upgraded to C from C- on 8/19/2019 due to a major increase in the growth index, efficiency index and solvency index. Total revenue increased 247.73% from $189.4 to $658.6, the quick ratio increased from 0.47 to 1.27, and EBIT increased 81.15% from -$349.1 to -$65.8.
INVO Bioscience, Inc. (IVOB) was upgraded to C from C- on 8/19/2019 due to a major increase in the growth index, efficiency index and solvency index. Total revenue increased 247.73% from $189.4 to $658.6, the quick ratio increased from 0.47 to 1.27, and EBIT increased 81.15% from -$349.1 to -$65.8.
C
Hold
8/15/2018Downgrade
INVO Bioscience, Inc. (IVOB) was downgraded to C- from C on 8/15/2018 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 1,188.94% from -$144.7 to -$1.87M, EBIT declined 1,176.12% from -$140.3 to -$1.79M, and earnings per share declined from -$0.001 to -$0.0127.
INVO Bioscience, Inc. (IVOB) was downgraded to C- from C on 8/15/2018 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 1,188.94% from -$144.7 to -$1.87M, EBIT declined 1,176.12% from -$140.3 to -$1.79M, and earnings per share declined from -$0.001 to -$0.0127.
C
Hold
5/14/2018Upgraded
INVO Bioscience, Inc. (IVOB) was upgraded to C from C- on 5/14/2018 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 28.83% from -$27.4 to -$19.5, and total revenue increased 19.35% from $68.2 to $81.4.
INVO Bioscience, Inc. (IVOB) was upgraded to C from C- on 5/14/2018 due to a significant increase in the total return index, efficiency index and growth index. Operating cash flow increased 28.83% from -$27.4 to -$19.5, and total revenue increased 19.35% from $68.2 to $81.4.
C
Hold
3/27/2018Upgraded
INVO Bioscience, Inc. (IVOB) was upgraded to C- from D+ on 3/27/2018 due to an increase in the volatility index and total return index.
INVO Bioscience, Inc. (IVOB) was upgraded to C- from D+ on 3/27/2018 due to an increase in the volatility index and total return index.
D
Sell
3/19/2018Upgraded
INVO Bioscience, Inc. (IVOB) was upgraded to D+ from D on 3/19/2018 due to an increase in the volatility index and total return index.
INVO Bioscience, Inc. (IVOB) was upgraded to D+ from D on 3/19/2018 due to an increase in the volatility index and total return index.
D
Sell
3/2/2018Downgrade
INVO Bioscience, Inc. (IVOB) was downgraded to D from D+ on 3/2/2018 due to a large decline in the total return index and volatility index.
INVO Bioscience, Inc. (IVOB) was downgraded to D from D+ on 3/2/2018 due to a large decline in the total return index and volatility index.
D
Sell
1/8/2018Downgrade
INVO Bioscience, Inc. (IVOB) was downgraded to D+ from C- on 1/8/2018 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 26.85% from -$21.6 to -$27.4, total revenue declined 15.07% from $80.3 to $68.2, and earnings per share declined from -$0.001 to -$0.0011.
INVO Bioscience, Inc. (IVOB) was downgraded to D+ from C- on 1/8/2018 due to a large decline in the growth index, volatility index and total return index. Operating cash flow declined 26.85% from -$21.6 to -$27.4, total revenue declined 15.07% from $80.3 to $68.2, and earnings per share declined from -$0.001 to -$0.0011.
C
Hold
9/8/2017Upgraded
INVO Bioscience, Inc. (INVO) was upgraded to C- from D on 09/08/2017.
INVO Bioscience, Inc. (INVO) was upgraded to C- from D on 09/08/2017.
D
Sell
8/14/2017Upgraded
INVO Bioscience, Inc. (IVOB) was upgraded to D from on 8/14/2017 due to a significant increase in the growth index, efficiency index and solvency index. Operating cash flow increased 80.85% from -$112.8 to -$21.6, total revenue increased 53.83% from $52.2 to $80.3, and net income increased 36.25% from -$214.9 to -$137.
INVO Bioscience, Inc. (IVOB) was upgraded to D from on 8/14/2017 due to a significant increase in the growth index, efficiency index and solvency index. Operating cash flow increased 80.85% from -$112.8 to -$21.6, total revenue increased 53.83% from $52.2 to $80.3, and net income increased 36.25% from -$214.9 to -$137.
NASDAQ
04/04/2025 12:18PM Eastern
Quotes delayed
